PTC Therapeutics (PTCT) Stock Price, News & Analysis

Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Key Stats

• Today's Range: $45.95 to $47.96
• 50-Day Range: $39.77 to $57.17
• 52-Week Range: $24.00 to $58.38
• Volume: 1.04 million shs
• Average Volume: 821,653 shs
• Market Capitalization: $3.74 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $63.77
• Consensus Rating: Moderate Buy

PTC Therapeutics Stock Analysis - MarketRank™

PTC Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 214th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 8 buy ratings, 4 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

PTC Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PTC Therapeutics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PTC Therapeutics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.44% of the float of PTC Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

PTC Therapeutics has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in PTC Therapeutics has recently increased by 26.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PTC Therapeutics does not currently pay a dividend.

Dividend Growth

PTC Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.38

Percentage of Shares Shorted

7.44% of the float of PTC Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

PTC Therapeutics has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in PTC Therapeutics has recently increased by 26.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.68

News Sentiment

PTC Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for PTC Therapeutics this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for PTCT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,546,088.00 in company stock.

Percentage Held by Insiders

Only 5.50% of the stock of PTC Therapeutics is held by insiders.

PTCT Stock Analysis - Frequently Asked Questions

How have PTCT shares performed this year?

PTC Therapeutics' stock was trading at $45.14 at the beginning of the year. Since then, PTCT shares have increased by 5.0% and is now trading at $47.39.
View the best growth stocks for 2025 here.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, topping analysts' consensus estimates of ($1.54) by $0.15. The biopharmaceutical company earned $196.79 million during the quarter, compared to analysts' expectations of $173.51 million.
Read the conference call transcript.

Who are PTC Therapeutics' major shareholders?

Top institutional investors of PTC Therapeutics include Assenagon Asset Management S.A. (0.43%), Rhumbline Advisers (0.14%), GAMMA Investing LLC (0.06%) and Harbor Capital Advisors Inc. (0.05%). Insiders that own company stock include Matthew B Klein, Stuart Walter Peltz, Michael Schmertzler, Mark Elliott Boulding, Neil Gregory Almstead, Eric Pauwels, Lee Scott Golden, Pierre Gravier, Christine Marie Utter, Emily Luisa Hill, Allan Steven Jacobson, Jerome B Zeldis, David P Southwell, Alethia Young, Stephanie Okey and Emma Reeve.
View institutional ownership trends.

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 4/18/2025
• Next Earnings (Estimated): 4/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTCT
• CIK: 1070081
• Web: www.ptcbio.com
• Phone: (908) 222-7000
• Fax: 908-222-7231
• Employees: 1,410
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $63.77
• High Stock Price Target: $113.00
• Low Stock Price Target: $42.00
• Potential Upside/Downside: +34.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.53
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-626,600,000.00
• Net Margins: -50.32%
• Pretax Margin: -47.24%
• Return on Equity: N/A
• Return on Assets: -16.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.10
• Quick Ratio: 2.04

Sales & Book Value

• Annual Sales: $806.78 million
• Price / Sales: 4.63
• Cash Flow: $2.28 per share
• Price / Cash Flow: 20.80
• Book Value: ($10.85) per share
• Price / Book: -4.37

Miscellaneous

• Outstanding Shares: 78,869,000
• Free Float: 72,883,000
• Market Cap: $3.74 billion
• Optionable: Optionable
• Beta: 0.58